REAL-WORLD CARDIAC SAFETY OF ANTI-HER2 THERAPIES IN ELDERLY PATIENTS WITH HER2+/HR-METASTATIC BREAST CANCER: A RETROSPECTIVE COHORT STUDY USING SEER-MEDICARE DATA 2012-2016

被引：0
|
作者：
Ou, Z. [1 ]
Nohria, A. [2 ]
Spring, L. M. [3 ]
Seeger, J. D. [4 ]
Doucette, J. [5 ]
Murimi-Worstell, I. B. [5 ]
机构：
[1] MCPHS Univ, Belmont, MA USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[4] Optum, Boston, MA USA
[5] MCPHS Univ, Boston, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA33
引用
收藏
页码：S610 / S610
页数：1
相关论文
共 50 条
  • [31] Real-world treatment patterns in patients with HER2+unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort
    Lee, Soo-Chin
    Chung, Wei-Pang
    Ngan, Roger Kai-Cheong
    Im, Seock-Ah
    Hui, Rina
    Barrios, Carlos
    Tung, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
    Liu, Xiaoyu
    Zhang, Peng
    Li, Chao
    Song, Xiang
    Liu, Zhaoyun
    Shao, Wenna
    Li, Sumei
    Wang, Xinzhao
    Yu, Zhiyong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2-breast cancer
    Kao, Yun-Chieh
    Tsai, Yi-Fang
    Shen, Shih-Che
    Dai, Ming-Shen
    Chen, Fang-Ming
    Liu, Liang-Chih
    Chao, Ta-Chung
    Huang, Chi-Cheng
    Hou, Ming-Feng
    Chen, Shin-Cheh
    Liu, Chun-Yu
    Tseng, Ling-Ming
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2025, 88 (01) : 26 - 33
  • [34] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
    K. Nozawa
    M. Terada
    M. Onishi
    Y. Ozaki
    T. Takano
    W. Fakhouri
    D. Novick
    J. M. Haro
    L. H. Faris
    T. Kawaguchi
    Y. Tanizawa
    Junji Tsurutani
    Breast Cancer, 2023, 30 : 657 - 665
  • [35] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR +, HER2-metastatic breast cancer patients in Japan
    Nozawa, K.
    Terada, M.
    Onishi, M.
    Ozaki, Y.
    Takano, T.
    Fakhouri, W.
    Novick, D.
    Haro, J. M.
    Faris, L. H.
    Kawaguchi, T.
    Tanizawa, Y.
    Tsurutani, Junji
    BREAST CANCER, 2023, 30 (04) : 657 - 665
  • [36] Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2-advanced breast cancer
    Hao, Chunfang
    Bai, Xuedong
    Zhang, Jie
    Meng, Wenjing
    Tong, Zhongsheng
    THORACIC CANCER, 2023, 14 (01) : 68 - 72
  • [37] Comprehensive analysis of anti-HER2 antibodies-insensitive HER2-positive breast cancer patients in neoadjuvant therapy: a multi-center real-world study
    Han, Y.
    Lan, B.
    Peng, Z.
    Jia, Y.
    Tian, X.
    Ji, D.
    Sang, D.
    Wang, J.
    Ma, F.
    Luo, Y.
    Zhang, P.
    Xu, B.
    Fan, Y.
    BREAST, 2025, 80
  • [38] Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study
    Li, Chao
    Sun, Luhao
    Liu, Zhaoyun
    Sun, Haiyin
    Wang, Xinzhao
    Yu, Qian
    Yu, Zhiyong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (02): : 869 - 879
  • [39] Efficacy and safety of disitamab vedotin after trastuzumab for HER2-positive breast cancer: A real-world data of retrospective study
    Li, C.
    Yu, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [40] Characterising HER2-low status in metastatic breast cancer: a real-world retrospective study of patients at a metropolitan cancer centre in Australia
    Li, Michelle
    Yeo, Belinda
    CANCER RESEARCH, 2024, 84 (09)
12345